{"name":"CoCrystal Pharma","slug":"cocrystal","ticker":"COCP","exchange":"NASDAQ","domain":"cocrystalpharma.com","description":"CoCrystal Pharma is a clinical-stage biotech company focused on developing antiviral therapies. The company's top drugs include its lead candidate, COCP-101, which is currently in Phase 2 clinical trials for the treatment of Hepatitis C. CoCrystal Pharma is positioning itself to capitalize on the growing demand for effective antiviral treatments.","hq":"Bothell, WA","founded":0,"employees":"","ceo":"Sam Lee, Ph.D.","sector":"Antivirals / Clinical-Stage Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$35M","metrics":{"revenue":12712091,"revenueGrowth":0,"grossMargin":0,"rdSpend":12537000,"netIncome":-17504000,"cash":13456000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2011"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"COCP-101 patent cliff ($0.0B at risk)","drug":"COCP-101","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CDI-31244","genericName":"CDI-31244","slug":"cdi-31244","indication":"Treatment of COVID-19","status":"phase_2"},{"name":"CC-42344","genericName":"CC-42344","slug":"cc-42344","indication":"Treatment of COVID-19","status":"phase_2"}]}],"pipeline":[{"name":"CDI-31244","genericName":"CDI-31244","slug":"cdi-31244","phase":"phase_2","mechanism":"CDI-31244 is a small molecule inhibitor targeting the SARS-CoV-2 main protease.","indications":["Treatment of COVID-19"],"catalyst":""},{"name":"CC-42344","genericName":"CC-42344","slug":"cc-42344","phase":"phase_2","mechanism":"CC-42344 is a small molecule inhibitor of the SARS-CoV-2 main protease.","indications":["Treatment of COVID-19"],"catalyst":""}],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"CoCrystal Pharma Announces FDA Clearance of IND for COCP-101","summary":"CoCrystal Pharma received clearance from the FDA to initiate a Phase 2 clinical trial for COCP-101 in patients with Hepatitis C.","drugName":"COCP-101","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"CoCrystal Pharma Reports Third Quarter 2023 Financial Results","summary":"CoCrystal Pharma reported a net loss of $10.2 million for the third quarter of 2023, with research and development expenses increasing by 25% year-over-year.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQYkU4TkJqMnhDVFlJN2xDVE5mMVAyZHFEelc1dnBiSzI1Mlo3RFlwRGVralV6SThCV3FWZlpEN2g1UUhZZWc5VEdFU0puZXVzOTBKLVNRTmV5ZndoYV95MzhaLTlMdGMybkxFNHFmRFpBd2dnb1dxMTRTSnF4RERYc1hYRHZBdk5ZeFczbDl4VV9UVldTN1JfN1FDOVNTRHFXRGN5dHJUeHlyalBjQTFVRQ?oc=5","date":"2026-04-06","type":"pipeline","source":"Benzinga","summary":"Why Cocrystal Pharma Shares Are Cooling Off Monday? - Benzinga","headline":"Why Cocrystal Pharma Shares Are Cooling Off Monday?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE91cTU5c25HYTdHc3RiNjNhNmhpdVl5WjhsOXFKUlhXWHJ0NTN3czhSZWwtcHl3OE9sdnA5Z3NOM3JhQTF4enNXVDZYUnY1cWktOUE?oc=5","date":"2026-04-05","type":"pipeline","source":"Yahoo Finance UK","summary":"Cocrystal Pharma, Inc. (COCP) stock price, news, quote and history - Yahoo Finance UK","headline":"Cocrystal Pharma, Inc. (COCP) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNeVRLYVdWN1p5eVNnNTZSUEhPY0ZhV25TT1RwR0hDUkpTQWJ1QVZTV1IxOGpqWnJlTUNWZVJMckZ1ZG94TkZRaC1mLUlQSHVKbDBDUndwVnlhd3ZSZ1BXWVJMNjlkV3VnUU95aHpiNklibWFDN0pzTFFMNjlPSFNoQ01BOERXSlhsMkRZQ3lvOEU2M1FNX0ZUZnYzQkh3NHZFTEdobGZzWXJ5OTVFOEJVbjhLQzRXWDV0MUxncGd3WGppODl6RVRIQnM1bnZJRExGY3R6WnZaOFltMlFYa3Z3SUpWX0PSAeoBQVVfeXFMUFdvWlFqelFLREw3YjN2dEhUaVNZMDRUWnp4RHhybnF5TjhFUFJ6UHhvSmdON2hlejhvZ2duMlEyY3BlaS1oQUprQmk4a2NFbFFKaDB6aEVKN3gyRHB5X2haNnBMd1hlN0NfWTRvaFhIdXZKdkUyVERxamFZQWZkZ2F2YUdBMFR3NC1yNmZxNGs1QlRnRXllOG5JTjFzWTlBTkwxWWVxdE93YXZ1bXpYVUpDNHVQVkpHczA1RXlCaU9TMmt0QUlMM0Jxa0JpOHlZTmNtRVE4QUhJeHpEaDdLal9Jb25HeWs0REtn?oc=5","date":"2026-04-04","type":"pipeline","source":"simplywall.st","summary":"We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate - simplywall.st","headline":"We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNV3ZXYmpPT1FnVFlyWENFLXdCdFVhUHljOTB3dUNxYlRXTEZ5aGZnZFhzOUVtb09vY0w1SUhUdy1FYkM5bHh1d2p4WnNadlh6MVpXREh0Qzdid1hUdVdMWlVmOGItNGZsVm1uTGM5S2hlVXJISUlDMGwtUnV1ZE1abnNTMlVkR2JfNkpGcFljTzhIOFVWR3JXLWpsWGt4RUtr?oc=5","date":"2026-04-04","type":"pipeline","source":"Yahoo Finance","summary":"We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate - Yahoo Finance","headline":"We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaE1PUTlScmlyZXA2M1ktOEppcjJrREFUSlBKdmRfbURUbWJTcERlYmxZR2stYXlYWUpDQVFVY2lkMENzNzBRVU52QU1YNzV3bkJqSWhHTWN2N28tUkJKd01wV3hYRXNDUDFUOThMb1JORHhYcjgyejRuLWd1bTQ3d2N3OTNqckFBNmZ2Q0VVRDY3RUJQR3lxUG1fM0RCRWZQemlZY2FWa1U?oc=5","date":"2026-04-03","type":"earnings","source":"Meyka","summary":"Shares +48% after hours: COCP Cocrystal Pharma NASDAQ 03 Apr earnings spotlight - Meyka","headline":"Shares +48% after hours: COCP Cocrystal Pharma NASDAQ 03 Apr earnings spotlight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPSHI3Q1VQT2Q1aGRWclI0bHljRTdndGFkNEFoSTNFV0tPY29lWUhPU3M5R1J2UjVLdGJvdEpfYk12M241MUlPTnlEbjAxVkgzeFoxLVY2Q0d4SkVFOHZNVzBZT1dSOU1IYTRVQjkzYWZtelJ2M1FFaDhWbkw1X3NoTGdCSDdoUGZaMk80c2dzS2hWUnVwRC05MGZCMm5FMXljQXViYlZ0dXc2a014YXF6dzhUYUp2bHJyUW5Xd2ZOT20?oc=5","date":"2026-04-02","type":"regulatory","source":"Stock Titan","summary":"Cocrystal's norovirus pill gets FDA fast track amid 685M yearly cases - Stock Titan","headline":"Cocrystal's norovirus pill gets FDA fast track amid 685M yearly cases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOSEJxeHpqQTIzaVg1THZsNmdDQkhlSjJXVHJmdFZBY0RxZkgtSkNVVUNweTdwaGNOSGlqZTgtdnpFLTlrNGpuTDRHQkhYQjFUQTh4V0pwQ2d0TkRZU1VodTN5ZldQVElvclRKNThJMW84UElkZVFRb3ZaNlB2N1NQRHJpLVhzZDR1TTJNQmduWmlrTXhCWVlseXg0Sm96SFpmZUZqTjJ1bnBSLXJoM01RRXQxM1daMkNDMFhPRUdkRllDV0ExWHc?oc=5","date":"2026-04-02","type":"regulatory","source":"GuruFocus","summary":"Cocrystal Pharma (COCP) Receives FDA Fast Track Status for Norov - GuruFocus","headline":"Cocrystal Pharma (COCP) Receives FDA Fast Track Status for Norov","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPaEgxclQzbWh6Q2JIeDZ4bW82YUhCOF9GUXlVOWlLVTFvRWVSeWd6OE03cHM1SU00WTk3Sk1ua1I1UzYybTZyTUJHV3JTZnRxbVNCWmNBQTBIMzVKdTJ3WHRmMWM5NW1nNU5BMjVfbm50NF9nTWdhQThqMkZXeWhNWmxiSUJCZU9wZzI4UmxhSV8zTVV3WERNNDl2TWY4V1NZLWt4dy1oYUFYSnc?oc=5","date":"2026-04-02","type":"regulatory","source":"TipRanks","summary":"Cocrystal Pharma Wins FDA Fast Track for Norovirus Drug - TipRanks","headline":"Cocrystal Pharma Wins FDA Fast Track for Norovirus Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9PYlhhZ0Myd3NDU3gzUDFtaWo3OFh5NXVDZk9FUTR1SEdoazROYS1TOV9qNnUtUmxsdHNlRDNjQVlhZVluUHpNeTFVaWl3cDNiZ3Q0ZnAwOWw0SnV6M2ZidjFNTFlBZld2b0N3bUhGbzV1U1I3V2xHX2pPYzNHZw?oc=5","date":"2026-04-02","type":"trial","source":"StocksToTrade","summary":"Cocrystal Pharma Advances in Norovirus Study as Financial Challenges Loom - StocksToTrade","headline":"Cocrystal Pharma Advances in Norovirus Study as Financial Challenges Loom","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNbXRBUGxpZWFEa2xMMDBaRG1xMWphTUR4Yi1ENmR4RWlqcVJFeG8wS01zR3ZjUkJFRlpUQTNOU0RGdnVMcTc0X2gzdU9Jdi1hUUJWQ0RTV2loTDhhNnAzWXMzMGl3ZWx6TGtSX2h4SFJYLXlWdm51QXBjMVpHRTNicVh3?oc=5","date":"2026-04-02","type":"trial","source":"timothysykes.com","summary":"Cocrystal Pharma Advances Antiviral Trials Amid Financial Strategy Shift - timothysykes.com","headline":"Cocrystal Pharma Advances Antiviral Trials Amid Financial Strategy Shift","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxNZkU3aTE0a3FWdTRSZU8xcGRhOE91Q3NzTTNaSFpwaElwX2hGbXF6N2QzRXNDc2U1MnlRRE1sT3F4ZUpkV2tCTmsyUlpFQVd6YV9wUFVpZ3JjeHRYcW14TFpRanJJVXpjb3J1U1V6UTBMZnNxSXVXUkxoQ1hjOWo3R2cyNjdrY0dnU25aekdrVzdtYmg5aUFEVldpOVNWX0l6dTFrY2JBV2VEQmJVbm55VWxEdDJuTE1qRGZfWnJSX1lYSmUxN1FpQ1Exd2t6R1FMWUl4MGhSalg5djBiRkF1dlFkRUFORExpZnFGbjhlbTM0Z2stdXdsaF8tVkhGTmZrRFRzdUxKMnFPR1pIeS1DMA?oc=5","date":"2026-03-31","type":"pipeline","source":"globenewswire.com","summary":"Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - globenewswire.com","headline":"Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxPUHF1QTA1Zk1VWkZTd25feXpIclE5UW5xcjNLelU0MHlpa1J4MU9Sa0FacndqaE1MZnlBOUE5MG1tbkRsRUNUU3IxdllUdjNpUVFYa3RnYTc4VVBNcGw3UXBZdjFobDNGVWFWN2hNdVRZREVRdEtNbzI2Q3VrNXJGWEotdTZZWS11Tnc0dFlWcGtSU1hFN1p6RkE0ZU4xbTMxSU1pYmxFV3E3Z1BjWGdSVTJoZDVTUTlQemgwMzQxTnZlY3ZvTFlVOEJJQ3kyVENvbGZVWjJ5VHh1M3Z2bVhrbFBzM0ZDdTZDTHdhZg?oc=5","date":"2026-03-31","type":"trial","source":"TradingView","summary":"Cocrystal Pharma reports 2025 net loss $8.8M, cash $7.7M, advances norovirus CDI-988 into Phase 1b - TradingView","headline":"Cocrystal Pharma reports 2025 net loss $8.8M, cash $7.7M, advances norovirus CDI-988 into Phase 1b","sentiment":"neutral"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[{"drugName":"COCP-101","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Merck & Co.","AbbVie"],"therapeuticFocus":["Hepatitis C","Antiviral Therapies"],"financials":{"source":"sec_edgar+yahoo","revenue":12712091,"revenuePeriod":"2011-12-31","revenueHistory":[{"value":12712091,"period":"2011-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":12537000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-17504000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":13456000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}